Updated:
Advanced Research Projects Agency for Health
Advanced Research Projects Agency for Health (ARPA-H) is a research funding agency based in Bethesda, Maryland. Founded in 2022, ARPA-H primarily supports...
Advanced Research Projects Agency for Health
Advanced Research Projects Agency for Health (ARPA-H) is a research funding agency based in Bethesda, Maryland. Founded in 2022, ARPA-H primarily supports biomedical and health research projects. The agency has made 35 investments, including a grant to SonoNeu on April 08, 2026.
General information
Firm type
other
Year founded
2022
Location
Region
North America
Country
United States
City
Washington
Corporate office
Washington, DC, United States
Principals
Renee Wegrzyn
Director
Sector focus
Frequently asked questions
Who runs investment decisions at ARPA-H?
Director Renee Wegrzyn sets the agency's strategic priorities, but individual program managers design and execute specific programs. These term-limited managers identify research gaps, write program solicitations, select performer teams, and have authority to modify or terminate projects based on milestone results. Governance and selection processes are outlined in the agency's authorizing statute and published funding announcements.
Is ARPA-H part of the NIH?
Yes, ARPA-H is established as an independent agency within the National Institutes of Health. It was authorized by Congress in the 2022 appropriations bill and reports to the Secretary of Health and Human Services, not the NIH Director directly. This structure gives it budgetary and operational independence from standard NIH peer-review processes.
What investment stages does ARPA-H typically target?
ARPA-H funds translational research — the chasm between basic science discoveries and clinically deployable products. Projects range from early proof-of-concept to preclinical validation and early-stage human trials. The agency intentionally avoids work that could be funded through standard NIH R01 grants or that has near-term commercial viability attractive to venture capital.
Does ARPA-H take equity in companies it funds?
No. ARPA-H does not take equity positions, nor does it expect a financial return. Its funding instruments are grants, cooperative agreements, and Other Transaction Agreements that may include milestone-based payments. Intellectual property terms are negotiated per award, generally allowing performers to retain ownership while granting the government certain use rights.
Which sectors does ARPA-H explicitly avoid?
The agency is structured to avoid incremental or near-certain advances. It does not fund late-stage clinical trials outside exceptional circumstances, nor does it support work that existing pharmaceutical development pipelines or NIH institutes are expected to pursue. It has no mandate in non-health technologies, defense-specific medical countermeasures, or pure basic science without a translational path.
How does ARPA-H source proposals?
ARPA-H program managers define program areas and publish Broad Agency Announcements, targeted solicitations, and prize challenges. Proposals are accepted from universities, nonprofit research institutes, and companies of any size. The agency also holds proposer days and outreach events to shape programs before formal solicitations are released.
What is ARPA-H's known posture on co-investment alongside external funders?
The agency actively encourages co-funding arrangements with other government entities, philanthropic foundations, and private investors. Several programs require or incentivize cost-sharing from performers or external partners. ARPA-H has publicly stated a goal of bridging projects from government support into commercial pathways where private capital can fund later development and scale-up.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: